JP7269167B2 - モジュラー四価二重特異性抗体プラットフォーム - Google Patents

モジュラー四価二重特異性抗体プラットフォーム Download PDF

Info

Publication number
JP7269167B2
JP7269167B2 JP2019520024A JP2019520024A JP7269167B2 JP 7269167 B2 JP7269167 B2 JP 7269167B2 JP 2019520024 A JP2019520024 A JP 2019520024A JP 2019520024 A JP2019520024 A JP 2019520024A JP 7269167 B2 JP7269167 B2 JP 7269167B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
domain
cdrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019520024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533675A (ja
JP2019533675A5 (https=
Inventor
ウェイン エー． マラスコ
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2019533675A publication Critical patent/JP2019533675A/ja
Publication of JP2019533675A5 publication Critical patent/JP2019533675A5/ja
Priority to JP2023069848A priority Critical patent/JP7796079B2/ja
Application granted granted Critical
Publication of JP7269167B2 publication Critical patent/JP7269167B2/ja
Priority to JP2025119440A priority patent/JP2025142045A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2019520024A 2016-10-14 2017-10-16 モジュラー四価二重特異性抗体プラットフォーム Active JP7269167B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023069848A JP7796079B2 (ja) 2016-10-14 2023-04-21 モジュラー四価二重特異性抗体プラットフォーム
JP2025119440A JP2025142045A (ja) 2016-10-14 2025-07-16 モジュラー四価二重特異性抗体プラットフォーム

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408271P 2016-10-14 2016-10-14
US62/408,271 2016-10-14
PCT/US2017/056814 WO2018071913A2 (en) 2016-10-14 2017-10-16 Modular tetrameric bispecific antibody platform

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023069848A Division JP7796079B2 (ja) 2016-10-14 2023-04-21 モジュラー四価二重特異性抗体プラットフォーム

Publications (3)

Publication Number Publication Date
JP2019533675A JP2019533675A (ja) 2019-11-21
JP2019533675A5 JP2019533675A5 (https=) 2020-11-26
JP7269167B2 true JP7269167B2 (ja) 2023-05-08

Family

ID=60327374

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019520024A Active JP7269167B2 (ja) 2016-10-14 2017-10-16 モジュラー四価二重特異性抗体プラットフォーム
JP2023069848A Active JP7796079B2 (ja) 2016-10-14 2023-04-21 モジュラー四価二重特異性抗体プラットフォーム
JP2025119440A Pending JP2025142045A (ja) 2016-10-14 2025-07-16 モジュラー四価二重特異性抗体プラットフォーム

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023069848A Active JP7796079B2 (ja) 2016-10-14 2023-04-21 モジュラー四価二重特異性抗体プラットフォーム
JP2025119440A Pending JP2025142045A (ja) 2016-10-14 2025-07-16 モジュラー四価二重特異性抗体プラットフォーム

Country Status (7)

Country Link
US (1) US20200017588A1 (https=)
EP (1) EP3526257A2 (https=)
JP (3) JP7269167B2 (https=)
CN (2) CN120795163A (https=)
AU (2) AU2017341936B2 (https=)
CA (1) CA3038504A1 (https=)
WO (1) WO2018071913A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900500TA (en) * 2016-07-22 2019-02-27 Dana Farber Cancer Inst Inc Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
JP7231549B2 (ja) * 2017-02-06 2023-03-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
CN119798453A (zh) * 2018-11-13 2025-04-11 Jn生物科学有限责任公司 激活免疫细胞的双特异性抗体
WO2020113164A1 (en) * 2018-11-30 2020-06-04 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
EP4069294A4 (en) * 2019-12-02 2024-07-10 Dana-Farber Cancer Institute, Inc. Antibodies against pd-l1 and methods of use thereof
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
WO2021226984A1 (zh) * 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
WO2023034288A1 (en) 2021-08-31 2023-03-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for treatment of autoimmune disorders and cancer
EP4436998A1 (en) 2021-11-24 2024-10-02 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
US20250255902A1 (en) 2022-03-09 2025-08-14 Dana-Farber Cancer Institute, Inc. Genetically engineered b cells and methods of use thereof
KR20250099103A (ko) 2022-08-15 2025-07-01 다나-파버 캔서 인스티튜트 인크. Cldn4에 대한 항체 및 이의 사용 방법
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
EP4731651A1 (en) * 2023-06-20 2026-04-29 Denali Therapeutics Inc. Dual transporters and methods of use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
JP2013515509A (ja) 2009-12-29 2013-05-09 エマージェント プロダクト デベロップメント シアトル， エルエルシー ヘテロダイマー結合タンパク質およびその使用
WO2013096346A1 (en) 2011-12-22 2013-06-27 Development Center For Biotechnology Bispecific t-cell activator antibody
JP2015513394A (ja) 2012-02-13 2015-05-14 シアトル チルドレンズ ホスピタル ドゥーイング ビジネ 二重特異性キメラ抗原受容体およびその治療的使用
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
JP2016516049A (ja) 2013-03-15 2016-06-02 メモリアル スローン−ケタリング キャンサー センター 多量体化技術
JP2016526878A (ja) 2013-05-20 2016-09-08 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
CA2452058A1 (en) * 2001-06-26 2003-01-09 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US7750123B2 (en) 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
WO2005054868A1 (en) * 2003-12-05 2005-06-16 Multimmune Gmbh Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases
WO2006089141A2 (en) 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
WO2007065027A2 (en) 2005-12-02 2007-06-07 Dana Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
US8962806B2 (en) 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
US8201615B2 (en) * 2008-02-22 2012-06-19 Dow Global Technologies Llc Heat storage devices
US9527924B2 (en) 2010-06-02 2016-12-27 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
CA2854806A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
LT2794658T (lt) * 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
WO2013092720A1 (en) 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
US9745381B2 (en) * 2012-05-18 2017-08-29 Scott & White Healthcare (Swh) Bispecific scFv immunofusion (BIf)
CA2886433C (en) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
ES2649991T3 (es) * 2012-11-19 2018-01-16 Baliopharm Ag Anticuerpo biespecífico recombinante que se une a CD20 y CD95
MX367668B (es) 2013-03-15 2019-08-30 Dana Farber Cancer Inst Inc Anticuerpos neutralizadores de flavivirus y métodos de uso de los mismos.
AR097306A1 (es) * 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
SG11201605093VA (en) * 2013-12-23 2016-07-28 Zymeworks Inc Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof
AU2015231164B2 (en) 2014-03-19 2020-04-09 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
EP3134111B1 (en) 2014-04-25 2022-06-08 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
PT3151921T (pt) * 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
JP2017531427A (ja) 2014-10-03 2017-10-26 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法
JP6795505B2 (ja) 2014-10-06 2020-12-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法
KR102668588B1 (ko) 2015-04-08 2024-05-22 다나-파버 캔서 인스티튜트 인크. 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법
WO2020113224A2 (en) * 2018-11-30 2020-06-04 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
JP2013515509A (ja) 2009-12-29 2013-05-09 エマージェント プロダクト デベロップメント シアトル， エルエルシー ヘテロダイマー結合タンパク質およびその使用
WO2013096346A1 (en) 2011-12-22 2013-06-27 Development Center For Biotechnology Bispecific t-cell activator antibody
JP2015513394A (ja) 2012-02-13 2015-05-14 シアトル チルドレンズ ホスピタル ドゥーイング ビジネ 二重特異性キメラ抗原受容体およびその治療的使用
JP2016516049A (ja) 2013-03-15 2016-06-02 メモリアル スローン−ケタリング キャンサー センター 多量体化技術
JP2016526878A (ja) 2013-05-20 2016-09-08 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FEBS LETTERS，1998年07月，Vol. 432, No. 1-2，pp. 45-49

Also Published As

Publication number Publication date
EP3526257A2 (en) 2019-08-21
AU2017341936A1 (en) 2019-04-04
CN110214152B (zh) 2025-06-13
CN120795163A (zh) 2025-10-17
CN110214152A (zh) 2019-09-06
CA3038504A1 (en) 2018-04-19
AU2017341936B2 (en) 2024-10-31
AU2025200665A1 (en) 2025-04-10
US20200017588A1 (en) 2020-01-16
JP2019533675A (ja) 2019-11-21
WO2018071913A3 (en) 2018-05-24
WO2018071913A2 (en) 2018-04-19
JP7796079B2 (ja) 2026-01-08
JP2023093642A (ja) 2023-07-04
JP2025142045A (ja) 2025-09-29

Similar Documents

Publication Publication Date Title
JP7269167B2 (ja) モジュラー四価二重特異性抗体プラットフォーム
AU2020286284B2 (en) Novel anti-CD39 antibodies
CN113166262B (zh) Pd-1单结构域抗体及其治疗组合物
CN115380047A (zh) Cd28单结构域抗体及其多价和多特异性构建体
JP2025020138A (ja) 免疫細胞活性化のための二重特異性抗体
CN111133003A (zh) 新型双特异性多肽复合物
TW202144437A (zh) 靶向ｏｘ４０及ｆａｐ之雙特異性抗原結合分子
JP2021521784A (ja) ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
KR102887991B1 (ko) 이중특이적 항pd-1 tim3 항체
KR20200104305A (ko) 삼중 사슬 항체(Triple-Chain Antibody)의 제조 방법 및 용도
JP7462611B2 (ja) Ｏｘ４０結合性ポリペプチド及びその使用
CN115484981A (zh) 用于调节免疫应答的材料和方法
AU2017233658A1 (en) Cell injury inducing therapeutic drug for use in cancer therapy
TW202216745A (zh) 包含經修飾ｉｌ－２多肽之多肽及其用途
CN114127112A (zh) 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
WO2022006451A2 (en) Compositions and methods for tcr reprogramming using fusion proteins and pd-1 antibodies
WO2022111576A1 (en) Novel conjugate molecules targeting cd39 and tgfβeta
KR20230047009A (ko) 암의 치료에 이용하기 위한 세포 상해 유도 치료제
KR20230156727A (ko) 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
KR20230146032A (ko) Tgf-b 신호전달을 조절하기 위한 세포 치료 조성물 및 방법
TWI919523B (zh) 5t4單域抗體及其治療性組合物
HK40085531A (en) Materials and methods for modulating an immune response
HK40010370A (en) Tri-chain antibody, preparation method and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201013

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201013

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210622

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230323

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230421

R150 Certificate of patent or registration of utility model

Ref document number: 7269167

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250